Ligand Pharmaceuticals Incorporated (LGND) Q2 2009 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Up 6.01%

Ligand Pharmaceuticals reported a smaller-than-expected loss per share, which led to a positive stock reaction, rising 6.01%. The lack of revenue figures leaves some uncertainty, but the EPS beat suggests better-than-anticipated performance in some areas. Investors may view this as a sign of resilience in challenging market conditions.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.04	N/A	+42.86%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management conveyed a cautious optimism about the company's direction. They acknowledged the positive EPS surprise but did not elaborate on revenue expectations.

Management expressed satisfaction with the EPS result despite not providing revenue figures.

They highlighted ongoing projects and potential future developments.

Ligand Pharmaceuticals Beats on EPS, Stock Up 6.01%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Up 6.01%

Key numbers

Management commentary